pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 11·1 min read
save

Long Covid research faces funding cut as NIH terminates grant, highlighting political neglect

Jun 11, 2026·read at STAT ↗Negative

Steven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeling it incompatible with agency priorities. The termination notice arrived in March 2025, just weeks before the data analysis was to be completed, leaving the researcher and patients disappointed.

The grant’s cancellation reflects a broader trend of long Covid being removed from federal attention. Phillips argues that attempts to fit the condition into traditional biomedical frameworks have failed, leading to its political erasure.

The article suggests that the decision was not an isolated incident but part of a systematic shift in policy that deprioritized long Covid research, leaving patients without the promised scientific insights.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: How long Covid’s scientific stalemate made it politically erasable”

read at STAT ↗
1,674 words · retrieved Jun 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Stanford University2HERITAGELEADINGNational Institutes of Health
topics
AdCom3Hematology2Infectious Disease2Vaccine2NeurologyOphthalmologyVaccines

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • 3h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Apr 30Opinion: Congress must hold RFK Jr. accountable after hearingsSTAT
  • Apr 28Predicting consequences of new hepatitis B vaccine recsSTAT